Full Press Release Details
Senesco Technologies Reports Second Quarter
of Fiscal Year 2014 Financial Results
BRIDGEWATER, N.J. (February 18, 2014) -
Senesco Technologies, Inc. ("Senesco" or the "Company") (OTCQB: SNTI) today announced financial results for
the three months ended December 31, 2013 ("Second Quarter 2014").
Fiscal Second Quarter and Recent Highlights
"We are excited to be in cohort 4,
at the top dose planned, of our Phase 1b/2a with SNS01-T," stated Leslie J. Browne, Ph.D, President and Chief Executive Officer
of Senesco "The study is progressing well and we expect to report top-line results by the end of June."
Second Quarter 2014 Financial Results
Research and development expenses for the
Second Quarter 2014 were $647,123, compared with $591,079 for the Second Quarter 2013, a 9.5% increase. The increase was primarily
due to an increase in costs incurred in connection with the development of the Company's drug candidate, SNS01-T, for multiple
myeloma due to the timing of patient recruitment, which was partially offset by a decrease in the cost associated with the research
contract with the University of Waterloo.
General and administrative expenses were
$941,784 for the Second Quarter 2014 compared with $708,968 for the Second Quarter 2013, a 32.8% increase. The increase was primarily
due to an increase in stock based compensation and investor relations costs, which was partially offset by a decrease in professional
The loss applicable to common shares for
the Second Quarter 2014 was $1,640,255 or $0.48 per share compared with a loss applicable to common shares for the Second Quarter
2013 of $1,293,871 or $1.11 per share.
As of December 31, 2013, the Company had
cash and cash equivalents in the amount of $6,121,895, compared to cash and cash equivalents of $1,602,294, as of June 30, 2013.
Senesco has initiated a Phase 1b/2a clinical
study for its drug candidate, SNS01-T, in multiple myeloma, diffuse large B-cell lymphoma and mantle cell lymphoma patients. Patients
are currently being treated in the fourth cohort of the trial. The Company plans to fund research and development and commercialization
activities by utilizing its current cash balance and investments, through the placement of equity and / or debt instruments, by
achieving milestones set forth in current licensing agreements, and through the execution of additional licensing agreements. The
Company believes that it has sufficient cash on hand to maintain operations at least through December 31, 2014.
About Senesco Technologies,
Senesco Technologies is a clinical-stage
biotech company specializing in cancer therapeutics. Its proprietary gene regulation technology has demonstrated the ability to
eliminate cancerous cells and protect healthy cells from premature death. The Company is currently in a phase 1b/2a trial with
a product that treats B-cell cancers, which include multiple myeloma, chronic lymphocytic leukemia, and non-Hodgkin's B-cell
lymphomas. The technology was developed over the last 15 years through the discovery that the genetic pathway for cell growth
control is common to both plants and humans. For more information, please visit Senesco.com
or connect with us on Facebook, Twitter, LinkedIn
SNS01-T is a novel approach to cancer therapy
that is designed to selectively trigger apoptosis in B-cell cancers such as multiple myeloma and mantle cell and diffuse large
B-cell lymphomas. Senesco is the sponsor of a Phase 1b/2a study that is actively enrolling patients at Mayo Clinic in Rochester,
MN, the University of Arkansas for Medical Sciences in Little Rock, AR, the Mary Babb Randolph Cancer Center in Morgantown, WV,
the John Theurer Cancer Center at Hackensack University Medical Center in Hackensack, NJ, and the Seattle Cancer Care Alliance
Forward-Looking Statements
Certain statements included
in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including,
but not limited to: the Company's ability to continue as a going concern; the Company's ability to recruit patients
for its clinical trial; the ability of the Company to consummate additional financings; the development of the Company's
gene technology; the approval of the Company's patent applications; the current uncertainty in the patent landscape surrounding
small inhibitory RNA and the Company's ability to successfully defend its intellectual property or obtain the necessary licenses
at a cost acceptable to the Company, if at all; the successful implementation of the Company's research and development programs
and collaborations; the success of the Company's license agreements; the acceptance by the market of the Company's products;
the timing and success of the Company's preliminary studies, preclinical research and clinical trials; competition and the
timing of projects and trends in future operating performance, the quotation of the Company's common stock on an over-the-counter
securities market, the Company's ability to execute a transaction with Fabrus, Inc., as well as other factors expressed from
time to time in the Company's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result,
this press release should be read in conjunction with the Company's periodic filings with the SEC. The forward-looking statements
contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update
such forward-looking statements to reflect subsequent events or circumstances.
RedChip Companies, Inc.
Tel: 1-800-RED-CHIP (733-2447), ext. 104
Email: info@redchip.com
| Joel Brooks | Heather Branham |
| Chief Financial Officer | 908-393-9393 |
| info@senesco.com |
| SENESCO TECHNOLOGIES, INC. AND SUBSIDIARY |
| (A DEVELOPMENT STAGE COMPANY) |
| CONDENSED CONSOLIDATED BALANCE SHEETS |
| December 31, | June 30, | |||||||
| 2013 | 2013 | |||||||
| ASSETS | ||||||||
| CURRENT ASSETS: | ||||||||
| Cash and cash equivalents | $ | 6,121,895 | $ | 1,602,294 | ||||
| Prepaid research supplies and expenses | 1,488,465 | 1,919,220 | ||||||
| Total Current Assets | 7,610,360 | 3,521,514 | ||||||
| Equipment, furniture and fixtures, net | 3,512 | 4,555 | ||||||
| Intangible assets, net | 3,482,388 | 3,566,497 | ||||||
| Security deposit | 5,171 | 5,171 | ||||||
| TOTAL ASSETS | $ | 11,101,431 | $ | 7,097,737 | ||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
| CURRENT LIABILITIES: | ||||||||
| Accounts payable | $ | 477,628 | $ | 637,320 | ||||
| Accrued expenses | 616,903 | 387,540 | ||||||
| Line of credit | 2,187,082 | 2,187,082 | ||||||
| Total Current Liabilities | 3,281,613 | 3,211,942 | ||||||
| Other liabilities | 99,728 | 99,728 | ||||||
| TOTAL LIABILITIES | 3,381,341 | 3,311,670 | ||||||
| COMMITMENTS | ||||||||
| STOCKHOLDERS' EQUITY: | ||||||||
| Convertible preferred stock, $0.01 par value, authorized 5,000,000 shares | ||||||||
| Series A 10,297 shares issued and 580 and 800 shares outstanding, respectively | ||||||||
| (liquidation preference of $594,500 and $820,000 | ||||||||
| at December 31, 2013 and June 30, 2013, respectively) | 6 | 8 | ||||||
| Common stock, $0.01 par value, authorized 500,000,000 shares, | ||||||||
| issued and outstanding 4,957,275 and 2,272,062, respectively | 49,573 | 22,721 | ||||||
| Capital in excess of par | 85,542,557 | 78,189,173 | ||||||
| Deficit accumulated during the development stage | (77,872,046 | ) | (74,425,835 | ) | ||||
| Total Stockholders' Equity | 7,720,090 | 3,786,067 | ||||||
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $ | 11,101,431 | $ | 7,097,737 |
| SENESCO TECHNOLOGIES, INC. AND SUBSIDIARY |
| (A DEVELOPMENT STAGE COMPANY) |
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS |
| Cumulative | ||||||||||||||||||||
| Three Months Ended December 31, | Six Months Ended December 31, | Amounts from | ||||||||||||||||||
| 2013 | 2012 | 2013 | 2012 | Inception | ||||||||||||||||
| Licensing Revenue | $ | - | $ | - | $ | 100,000 | $ | - | $ | 1,890,000 | ||||||||||
| Operating expenses: | ||||||||||||||||||||
| General and administrative | 941,784 | 708,968 | 1,882,233 | 1,441,688 | 35,996,534 | |||||||||||||||
| Research and development | 647,123 | 591,079 | 1,374,242 | 1,104,512 | 24,696,513 | |||||||||||||||
| Write-off of patents abandoned | - | - | 185,161 | - | 2,158,595 | |||||||||||||||
| Total operating expenses | 1,588,907 | 1,300,047 | 3,441,636 | 2,546,200 | 62,851,642 | |||||||||||||||
| Loss from operations | (1,588,907 | ) | (1,300,047 | ) | (3,341,636 | ) | (2,546,200 | ) | (60,961,642 | ) | ||||||||||
| Other non-operating income (expense) | ||||||||||||||||||||
| Grant income | - | - | - | - | 244,479 | |||||||||||||||
| Change in fair value of warrant liability | - | 64,440 | - | 44,292 | 8,701,721 | |||||||||||||||
| Sale of state income tax loss - net | - | - | - | - | 586,442 | |||||||||||||||
| Other noncash (expense) income, net | - | - | - | - | 205,390 | |||||||||||||||
| Loss on settlement of warrant liabilities | - | - | - | (785,171 | ) | (1,724,546 | ) | |||||||||||||
| Loss on extinguishment of debt | - | - | (361,877 | ) | ||||||||||||||||
| Amortization of debt discount and financing costs | - | - | - | - | (11,227,870 | ) | ||||||||||||||
| Interest expense - convertible notes | - | - | - | - | (2,027,930 | ) | ||||||||||||||
| Interest (expense) income - net | (30,731 | ) | (34,278 | ) | (62,335 | ) | (68,260 | ) | 102,566 | |||||||||||
| Net loss | (1,619,638 | ) | (1,269,885 | ) | (3,403,971 | ) | (3,355,339 | ) | (66,463,267 | ) | ||||||||||
| Preferred dividends | (20,617 | ) | (23,986 | ) | (42,240 | ) | (648,155 | ) | (11,408,779 | ) | ||||||||||
| Loss applicable to common shares | (1,640,255 | ) | (1,293,871 | ) | (3,446,211 | ) | (4,003,494 | ) | (77,872,046 | ) | ||||||||||
| Other comprehensive loss | - | - | - | - | - | |||||||||||||||
| Comprehensive loss | $ | (1,640,255 | ) | $ | (1,293,871 | ) | $ | (3,446,211 | ) | $ | (4,003,494 | ) | $ | (77,872,046 | ) | |||||
| Basic and diluted net loss per common share | $ | (0.48 | ) | $ | (1.11 | ) | $ | (1.20 | ) | $ | (3.57 | ) | ||||||||
| Basic and diluted weighted-average number | ||||||||||||||||||||
| of common shares outstanding | 3,443,109 | 1,169,753 | 2,875,517 | 1,122,123 |